Embecta Corp./$EMBC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Ticker
$EMBC
Sector
Primary listing
Employees
1,850
Headquarters
Website
Embecta Corp. Metrics
BasicAdvanced
$216m
1.93
$1.88
1.05
$0.46
1.10%
Price and volume
Market cap
$216m
Beta
1.05
52-week high
$15.55
52-week low
$2.77
Average daily volume
2m
Dividend rate
$0.46
Financial strength
Current ratio
2.459
Quick ratio
1.342
Long term debt to equity
-214.774
Total debt to equity
-216.85
Dividend payout ratio (TTM)
31.55%
Interest coverage (TTM)
2.79%
Profitability
EBITDA (TTM)
332.3
Gross margin (TTM)
61.84%
Net profit margin (TTM)
10.73%
Operating margin (TTM)
27.77%
Effective tax rate (TTM)
34.02%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
16.84%
Return on equity (TTM)
-16.43%
Valuation
Price to earnings (TTM)
1.932
Price to revenue (TTM)
0.205
Price to book
-0.34
Price to tangible book (TTM)
-0.33
Price to free cash flow (TTM)
1.045
Free cash flow yield (TTM)
95.69%
Free cash flow per share (TTM)
3.483
Dividend yield (TTM)
12.64%
Forward dividend yield
1.10%
Growth
Revenue change (TTM)
-3.43%
Earnings per share change (TTM)
111.16%
3-year revenue growth (CAGR)
-2.32%
3-year earnings per share growth (CAGR)
4.80%
3-year dividend per share growth (CAGR)
10.06%
What the Analysts think about Embecta Corp.
Analyst ratings (Buy, Hold, Sell) for Embecta Corp. stock.
Embecta Corp. Financial Performance
Revenues and expenses
Embecta Corp. Earnings Performance
Company profitability
Embecta Corp. News
AllArticlesVideos
EMBECTA DEADLINE: ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Embecta Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - EMBC
Newsfile Corp·4 hours ago
EMBC CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Embecta Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Newsfile Corp·20 hours ago
EMBECTA DEADLINE: ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages Embecta Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - EMBC
Newsfile Corp·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.